EGFR and non-small cell lung carcinoma: Based on these results, gefitinib was approved by the FDA (US Food and Drug Administration) in 2015 and erlotinib in 2016 for the treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.